


**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Chiaur *et al.*

Serial No.: 10/652,928

Filed: August 28, 2003

For: METHODS TO IDENTIFY COMPOUNDS  
USEFUL FOR THE TREATMENT OF  
PROLIFERATIVE AND DIFFERENTIATIVE  
DISORDERS



Confirmation No.: 5264

Art Unit: 1656

Examiner: David J. Steadman

Attorney Docket No: 5914-099-999  
CAM No.: 007402-999098

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

Enclosures accompanying this Information Disclosure Statement are: (i) a Substitute For Form 1449/PTO, entitled "Information Disclosure Statement By Applicant" listing References **AO1-A04, B01-B08 and C01-C106**; and (ii) a copy of References **C62-C106**.

This application is a continuation-in-part application under 37 C.F.R. §1.53(b) of Application No. 09/385,219, filed August 27, 1999, now Patent No. 6,720,181. References A01-A04, B01-B08 and C01-C61 were previously submitted and/or cited in prior Application No. 09/385,219, filed August 27, 1999, now Patent No. 6,720,181. Therefore, copies of these references are not being submitted pursuant to 37 C.F.R. §1.98(d), unless required by the Examiner.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise

closes prosecution in the application.. Please charge the \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) and any other fee that may be charged in connection with the submission of this Information Disclosure Statement to Jones Day Deposit Account No. 50-3013. A copy of this paper is enclosed for accounting purposes.

No admission is made that the information cited in this Statement is, or is considered to be, material to patentability and no representation is made that a search has been made. 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date: February 8, 2007


Laura A. Coruzzi 30,742  
Laura A. Coruzzi Reg. No.

By: Jacqueline Benn 43,492  
Jacqueline Benn (Reg. No.)  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, N.Y. 10017-6702  
212-326-3939

Enclosures

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

**ATTY. DOCKET NO.**

5914-099-999

**APPLICATION NO.**

10/652,928

**APPLICANT**

Chiaur et al.

**FILING DATE**

August 28, 2003

**ART UNIT**

1656

**U.S. PATENT DOCUMENTS**

*Examiner Initials		Document Number	Date Mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A01	4,873,191	10/ 0/1989	Wagner et al.	
	A02	5,093,246	03/03/1992	Cech et al.	
	A03	5,519,003	05/21/1996	Mochly-Rosen et al.	
	A04	5,981,702	11/9/1999	Zhang et al.	

**PATENT DOCUMENTS**

*Examiner Initials		Foreign Patent Document Country Code, Number, Kind Code (if known)	Date Mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
	B01	WO 89/10134	04/25/1989	The Regents of the University of California		
	B02	WO 95/021252	08/10/1995	The Board of Trustees of the Leland Stanford Junior University		
	B03	WO 97/011176	03/27/1997	Cold Spring Harbor Laboratory et al.		
	B04	WO 99/031252	06/24/1999	Incyte Pharmaceuticals, Inc.		
	B05	WO 99/018989	04/22/1999	Baylor College of Medicine		
	B06	WO 99/038969	08/05/1999	Institut National de la Sante Et de la Recherche Medicale		
	B07	WO 00/022110	04/20/2000	President and Fellows of Harvard College		
	B08	WO 00/034447	06/15/2000	Signal Pharmaceuticals, Inc. et al.		


**NON PATENT LITERATURE DOCUMENTS**

*Examiner Initials		Include name of the author (in CAPITAL LETTERS), (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	C01	AUFFRAY et al., 1994, EST Database Accession No. Z43904	
	C02	BAI et al., 1996, "SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box," Cell 86:263-274	
	C03	CARRANO et al., 1999, "SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27," Nature Cell Biol. 1:193	

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 5914-099-999	<b>APPLICATION NO.</b> 10/652,928
	<b>APPLICANT</b> Chiaur et al.	
	<b>FILING DATE</b> August 28, 2003	<b>ART UNIT</b> 1656




### U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date Mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	C04	CENCIARELLI et al., 1999, "Identification of a family of human F-box proteins," Curr. Biol. 9:1177-1179			
	C05	CHIAUR et al., 2000, "Five human genes encoding F-box proteins: chromosome mapping and analysis in human tumors," Cytogenet. Cell Genet. 88(3-4):255-8			
	C06	CIECHANOVER, 1994, "The ubiquitin-proteasome proteolytic pathway," Cell 79:13-21			
	C07	CIECHANOVER, 1998, "The ubiquitin-proteasome pathway: on protein death and cell life," EMBO J. 17:7151			
	C08	CAMERON, 1997, "Recent advances in transgenic technology," Mol. Biotechnol. 77:253-65			
	C09	DESHAIES, 1999, "SCF and Cullin/Ring H2-based ubiquitin ligases," Ann. Rev. Cell Dev. Biol. 15:435-67			
	C10	ESPOSITO et al., 1997, "Prognostic role of the cell cycle inhibitor p27 in non-small cell lung cancer," Cancer Research 57:3381-3385			
	C11	GONEN et al., 1999, "Identification of the ubiquitin-carrier proteins, E2s, involved in signal-induced degradation of I $\kappa$ B $\alpha$ ," J. Biol. Chem. 274:14823-14830			
	C12	HAMMER et al., 1990, "Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders," Cell. 63(5):1099-112			
	C13	HAWKINS et al., 1997, Genbank Accession No. AC001226			
	C14	HOCHSTRASSER, 1995, "Ubiquitin, proteasomes, and the regulation of intracellular protein degradation," Curr. Op. Cell Biol. 7:215-223			
	C15	HUNTER et al., 1994, "Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age," Cell 79:573			
	C16	JIANG et al., 1998, "Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb," Nature 29:391:493-496			
	C17	KAISER et al., 1998, "Cdc34 and the F-box protein Met30 are required for degradation of the Cdk-inhibitory kinase Swe1," Genes Dev. 12(16):2587-2597			
	C18	KEYOMARSI et al., 1995, "Deregulation of cyclin E in breast cancer," Oncogene 11:941-950			
	C19	KIPREOS et al., 1996, "cul-1 is required for cell cycle exit in C. elegans and identifies a novel gene family," Cell 85:829			
	C20	KLOCKARS et al., 2000, Genbank Accession No. AF126028			
	C21	KOCH et al., 1991, "SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins," Science 252:668-674			
	C22	KOEPP et al., 1999, "How the cyclin became a cyclin: regulated proteolysis in the cell cycle," Cell 97:431-433			
	C23	LANDSCHULTZ et al., 1988, "The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins," Science 240:1759-1764			

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

**ATTY. DOCKET NO.**

5914-099-999

**APPLICATION NO.**

10/652,928

**APPLICANT**

Chiaur et al.

**FILING DATE**

August 28, 2003

**ART UNIT**

1656

**U.S. PATENT DOCUMENTS**

*Examiner Initials		Document Number	Date Mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	C24	LATRES et al., 2001, "Role of the F-box protein Skp2 in lymphomagenesis," Proc. Natl. Acad. Sci. USA 98:2515-2520			
	C25	LATRES, 1999, "The human F box protein $\beta$ -Trcp associates with the Cul1/Skp1 complex and regulates the stability of $\beta$ -catenin," Oncogene 18:849-854			
	C26	LLOYD, 1999, "p27 <sup>kpl</sup> : a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers," Am. J. Pathol. 154:313-323			
	C27	LODA et al., 1997, "Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas," Nature Medicine 3:231-234			
	C28	LYAPINA, 1998, "Human CUL1 forms an evolutionarily conserved ubiquitin ligase complex (SCF) with SKP1 and an F-box protein," Proc. Natl. Acad. Sci. USA 95:7451-7476			
	C29	MARGOTTIN et al., 1998, "A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif," Molecular Cell 1:565-574			
	C30	MARIKAWA et al., 1998, " $\beta$ -TrCP is a negative regulator of <i>Wnt</i> / $\beta$ -catenin signaling pathway and dorsal axis formation in <i>Xenopus</i> embryos," Mech. Dev. 77(1):75-80			
	C31	MONTAGNOLI et al., 1999, "Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation," Genes and Dev. 13:1181			
	C32	MULLINS et al., 1993, "Transgenesis in nonmurine species," Hypertension 22(4):630-3			
	C33	NEER et al., 1994, "The ancient regulatory-protein family of WD-repeat proteins," Nature 371:297-300			
	C34	OHTSUBO et al., 1995, "Human cyclin E, a nuclear protein essential for the G <sub>1</sub> -to-S phase transition," Cell Biol. 15:2612-2624			
	C35	PAGANO et al., 1992, "Association of cdk2 kinase with the transcription factor E2F during S phase," Science 255:1144-1147			
	C36	PAGANO et al., 1992, "Cyclin A is required at two points in the human cell cycle," EMBO J.: 11(3):961-971			
	C37	PAGANO et al., 1995, "Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27," Science 269:682-685			
	C38	PAGANO, 1993, "Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts," J. Cell Bio. 121:101-111			
	C39	PAGANO, 1995, "From peptide purified antibody," in Cell Cycle: Materials and Methods, M. Pagano, ed., Springer-Verlag, pp. 217-281			
	C40	PAGANO, 1997, "Cell cycle regulation by the ubiquitin pathway," FASEB J. 11:1067-1075			
	C41	PATTON et al., 1998, "Combinatorial control in ubiquitin-dependent proteolysis: don't Skp the F-box hypothesis," Trends Genet. 14(6):236-243			
	C42	PEIFER, 1997, " $\beta$ -catenin as oncogene: the smoking gun," Science 275:1752-1753			

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 5914-099-999	<b>APPLICATION NO.</b> 10/652,928
	<b>APPLICANT</b> Chiaur et al.	
	<b>FILING DATE</b> August 28, 2003	<b>ART UNIT</b> 1656

**U.S. PATENT DOCUMENTS**

*Examiner Initials	Document Number	Date Mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	C43		PORTER et al., 1997, Expression of cell-cycle regulators p27 <sup>Kip1</sup> and cyclin E, alone and in combination, correlate with survival in young breast cancer patients," Nature Medicine 3:222	
	C44		ROLFE et al., 1997, "The ubiquitin-mediated proteolytic pathway as a therapeutic area," J. Mol. Med. 75:5-17	
	C45		RUDINGER, 1976, "Characteristics of the amino acids as components of a peptide hormone sequence," edited by J.A. Parsons, pp. 1-7, University Park Press, Baltimore	
	C46		SEAMARK, 1994, "Progress and emerging problems in livestock transgenesis: a summary perspective," Reprod Fertil Dev. 6(5):653-7	
	C47		SHEAFF et al., 1997, "Cyclin E-CDK2 is a regulator of p27 <sup>Kip1</sup> ," Genes Dev. 11:1464-1478	
	C48		SHERR et al., 1995, "Inhibitors of mammalian G <sub>1</sub> cyclin-dependent kinases,," Genes Dev. 9:1149-1163	
	C49		SHERR et al., 1999, "CDK inhibitors: positive and negative regulators of G <sub>1</sub> -phase progression," Genes & Dev. 13(12):1501-1512	
	C50		SINGH et al., 1998, "Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma," Cancer Research 58:1730-1735	
	C51		SKOWYRA et al., 1997, "F-box proteins are receptors that recruit phosphorylated substrates to the SCP-ubiquitin-ligase complex," Cell 91:209-219	
	C52		SPATARO, 1998, "The ubiquitin-proteasome pathway in cancer," Br. J. Cancer 77:448-455	
	C53		TAN et al., 1997, "The cell cycle inhibitor p27 is an independent marker in small (T <sub>1a,b</sub> ) invasive breast carcinomas," Cancer Research 57:1259-1263	
	C54		THOMAS et al., 1998, "Downregulation of p27 is associated with development of colorectal adenocarcinoma metastases," Am. J. Pathol. 153:681-687	
	C55		WINSTON et al., 1999, "A family of mammalian F-box proteins," Curr. Biol. 9:1180-1182	
	C56		WINSTON et al., 1999, "The SCF <sup>B-TRCP</sup> -ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IκBα and β-catenin and stimulates IκBα ubiquitination in vitro," Genes Dev. 13:270-283	
	C57		<a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a> (National Center for Biotechnology Information) GenBank Accession No. AF129532 (Homo sapiens chromosome 13 F-box protein Fbl3a (FBL3A) mRNA, partial cds) Database [Online]. Accessed on March 9, 2001. Released from GenBank on October 31, 1999	
	C58		<a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a> (National Center for Biotechnology Information) GenBank Accession No. AF17621 (Mus musculus leucine-rich repeat-containing F-box protein FBL3a mRNA, partial cds) Database [Online]. Accessed on March 9, 2001. Released from GenBank on December 6, 1999	
	C59		YARON et al., 1998, "Identification of the receptor component of the IκBα-ubiquitin ligase," Nature 396:590-594	
	C60		ZACHARIAE et al., 1999, "Whose end is destruction: cell division and the anaphase-promoting complex," Genes Dev. 13:2039-58	

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)		<b>ATTY. DOCKET NO.</b> 5914-099-999	<b>APPLICATION NO.</b> 10/652,928
	<b>APPLICANT</b> Chiaur et al.		
	<b>FILING DATE</b> August 28, 2003	<b>ART UNIT</b> 1656	

### U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Date Mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	C61	ZHANG et al., 1995, "p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase," Cell 82:915-925			
	C62	BALCZON et al., 1995, "Dissociation of centrosome replication events from cycles of DNA synthesis and mitotic division in hydroxyurea-arrested Chinese hamster ovary cells," J. Cell Biol. 130(1):105-15			
	C63	BROWN et al., 1997, "Mechanism of p53 degradation," Biochim. Biophys. Acta. 1332:01-6			
	C64	DAVIS et al., 2002, "Pseudosubstrate regulation of the SCF(beta-TrCP) ubiquitin ligase by hnRNP-U," Genes Dev. 16:439-51			
	C65	DONG et al., 1997, "Control of G1 in the developing Drosophila eye: rca1 regulates Cyclin A," Genes Dev. 11(1):94-105			
	C66	FONG et al., 2002, "S9, a 19 S proteasome subunit interacting with ubiquitinated NF-kappaB2/p100," J. Biol. Chem. 277(43):40697-702			
	C67	FREED et al., 1999, "Components of an SCF ubiquitin ligase localize to the centrosome and regulate the centrosome duplication cycle," Genes Dev. 13:2242-57			
	C68	FUCHS et al., 1999, "HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IkappaB and beta-catenin," Oncogene 18:2039-46			
	C69	FUKUCHI et al., 2001, "Ligand-dependent degradation of Smad3 by a ubiquitin ligase complex of ROC1 and associated proteins," Mol. Biol. Cell. 12(5):1431-43			
	C70	FURUKAWA et al., 2000, "The CUL1 C-terminal sequence and ROC1 are required for efficient nuclear accumulation, NEDD8 modification, and ubiquitin ligase activity of CUL1," Mol. Cell. Biol. 20(21):8185-97			
	C71	GARD et al., 1990, "Centrosome duplication continues in cycloheximide-treated Xenopus blastulae in the absence of a detectable cell cycle," J. Cell. Biol. 110(6):2033-42			
	C72	GIRARD et al., 1995, "Delayed cyclin A and B1 degradation in non-transformed mammalian cells," J. Cell. Sci. 108:2599-608			
	C73	GSTAIGER et al., 1999, "Association of human SCF(SKP2) subunit p19(SKP1) with interphase centrosomes and mitotic spindle poles," Exp. Cell. Res. 247:554-62			
	C74	HART et al., 1999, "The F-box protein beta-TrCP associates with phosphorylated beta-catenin and regulates its activity in the cell," Curr. Biol. 9:207-10			
	C75	HATAKEYAMA et al., 1999 "Ubiquitin-dependent degradation of IkappaBalpha is mediated by a ubiquitin ligase Skp1/Cul 1/F-box protein FWD1," Proc. Natl. Acad. Sci. 96:3859-63			
	C76	HATTORI et al., 1999, "Molecular dissection of the interactions among IkappaBalpha, FWD1, and Skp1 required for ubiquitin-mediated proteolysis of IkappaBalpha," J. Biol. Chem. 274: 29641-7			
	C77	HSU et al., 2002, "E2F-dependent accumulation of hEmil regulates S phase entry by inhibiting APCCdh1," Nat. Cell. Biol. 4:358-66			
	C78	KIPREOS et al., 2000, "The F-box protein family," Genome Biol. 2000;1(5): 3002.1-.7			

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b>	<b>APPLICATION NO.</b>
	5914-099-999	10/652,928
	<b>APPLICANT</b> Chiaur et al.	
	<b>FILING DATE</b>	<b>ART UNIT</b>
	August 28, 2003	1656


**U.S. PATENT DOCUMENTS**

*Examiner Initials		Document Number	Date Mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	C79	KITAGAWA et al., 1999, "An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of beta-catenin," EMBO J. 18(9):2401-10			
	C80	KOIKE et al., 2000, "Molecular cloning and genomic structure of the betaTRCP2 gene on chromosome 5q35.1," Biochem. Biophys. Res. Commun. 269:103-9			
	C81	KROLL et al., 1999, "Inducible Degradation of IB by the Proteasome Requires Interaction with the F-box Protein h-TrCP," J. Biol. Chem. 274(12):7941-5			
	C82	LASSOT et al., 2001, "ATF4 degradation relies on a phosphorylation-dependent interaction with the SCF(betaTrCP) ubiquitin ligase," Mol. Cell. Biol. 21(6):2192-202			
	C83	MARUYAMA et al., 2001, "Characterization of a mouse gene (Fbxw6) that encodes a homologue of Caenorhabditis elegans SEL-10," Genomics 78(3):214-22			
	C84	MATSUMOTO et al., 1999, "Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells," Curr. Biol. 9:429-32			
	C85	MERALDI et al., 1999, "Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A," Nat. Cell. Biol. 1:88-93			
	C86	NAKAYAMA et al., 2000, "Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication," EMBO J. 19(9):2069-81			
	C87	OHTA et al., 1999, "ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity," Mol. Cell. 3:535-41			
	C88	ORIAN et al., 2000, "SCF(beta)(-TrCP) ubiquitin ligase-mediated processing of NF-kappaB p105 requires phosphorylation of its C-terminus by IkappaB kinase," EMBO J. 19(11):2580-91			
	C89	OSAKA et al., 1998, "A new NEDD8-ligating system for cullin-4A," Genes Dev. 12:2263-8			
	C90	PETERS, 2002, "The anaphase-promoting complex: proteolysis in mitosis and beyond," Mol. Cell. 9:931-43			
	C91	PIVA et al., 2002, "In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation," Mol. Cell. Biol. 22(23):8375-87			
	C92	PODUST et al., 2000, "A Nedd8 conjugation pathway is essential for proteolytic targeting of p27Kip1 by ubiquitination," Proc. Natl. Acad. Sci 97(9):4579-84			
	C93	READ et al., 2000, "Nedd8 modification of cul-1 activates SCF(beta(TrCP))-dependent ubiquitination of IkappaBalpha," Mol. Cell. Biol. 20(7):2326-33			
	C94	REIMANN et al., 2001, "Emi1 is a mitotic regulator that interacts with Cdc20 and inhibits the anaphase promoting complex," Cell. 105(5):645-55			
	C95	REIMANN et al., 2001, "Emi1 regulates the anaphase-promoting complex by a different mechanism than Mad2 proteins," Genes Dev. 15(24):3278-85			
	C96	REIMANN et al., 2002, "Emi1 is required for cytostatic factor arrest in vertebrate eggs," Nature 416(6883):850-4			

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 5914-099-999	<b>APPLICATION NO.</b> 10/652,928
	<b>APPLICANT</b> Chiaur et al.	
	<b>FILING DATE</b> August 28, 2003	<b>ART UNIT</b> 1656



### U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Date Mm/dd/yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	C97		REYNARD et al., 2000, "Cks1 Is Required for G1 Cyclin-Cyclin-Dependent Kinase Activity in Budding Yeast," Mol. Cell. Biol. 20(16):5858-64	
	C98		SHIRANE et al., 1999, "Common pathway for the ubiquitination of IkappaBalpaha, IkappaBbeta, and IkappaBepsilon mediated by the F-box protein FWD1," J. Biol. Chem. 274(40):28169-74	
	C99		SPENCER et al., 1999, "Signal-induced ubiquitination of IkappaBalpaha by the F-box protein Slimb/beta-TrCP," Genes Dev. 13(3):284-94	
	C100		SUZUKI et al., 1999, "IkappaBalpaha ubiquitination is catalyzed by an SCF-like complex containing Skp1, cullin-1, and two F-box/WD40-repeat proteins, betaTrCP1 and betaTrCP2," Biochem. Biophys. Res. Commun. 256:127-32	
	C101		TAN et al., 1999, "Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of I kappa B alpha," Mol. Cell. 3:527-33	
	C102		WOJCIK et al., 2000, "The SCF ubiquitin ligase protein slimb regulates centrosome duplication in Drosophila," Curr. Biol. 10:1131-4	
	C103		WU et al., 1999, "beta-TrCP mediates the signal-induced ubiquitination of IkappaBbeta," J. Biol. Chem. 274(42):29591-4	
	C104		WU et al., 2000, "Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization," J. Biol. Chem. 275(41):32317-24	
	C105		YEH et al, 2000, "Ubiquitin-like proteins: new wines in new bottles," Gene 248:1-14	
	C106		YU et al., 1998, "Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins," Proc. Natl. Acad. Sci. 95:11324-9	

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	